Objective: This clinical study aimed to evaluate the efficacy of the therapy of warming the lung to reduce watery phlegm for treating non-small cell lung cancer(NSCLC) with malignant pleural effusion(MPE). Method: In this study

63 NSCLC patients with MPE were randomly divided into test group and control group

with 36 patients in test group and 27 patients in control group. The test group received the Chinese medicine therapy of warming the lung to reduce watery phlegm combined with chemotherapy with cisplatin treatment through pleural effusion. The control group received single chemotherapy with cisplatin treatment through pleural effusion. The primary observation index was disease stabilization rate (DSR) of MPE

the secondary observation indexes included karnofsky(KPS)

traditional symptoms

toxicities and median survival time(MST). Result: We evaluated all the 63 patients. The DSR of MPE was 94.44%(34 patients) in the test group and 77.78% (21 patients) in the control group(P<0.05). Compared to the control were

the KPS and traditional symptoms were both better. No unexpected toxicities were observed. The MST was 11.0 months in the test group and 7.5 months in the control group (hazard ratio[HR=0.21

95%CI(0.12

0.37)

P<0.05]. Conclusion: The Chinese medicine therapy of warming the lung to reduce watery phlegm combined with chemotherapy with cisplatin treatment through pleural effusion is effective to NSCLC with MPE.